• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 4:39:06 PM ET
    $XERS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XERS alert in real time by email
    SC 13G/A 1 fp0062370_sc13ga.htm

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (AMENDMENT NO. 1)*

     

    XERIS PHARMACEUTICALS INC

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    98422L107

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ]Rule 13d-1(b)
    [  ]Rule 13d-1(c)
    [x]Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 98422L107   13G   Page 1 of 9 Pages
         
    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital (Master), L.P.

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    [   ]

    (b)    [   ]

     
    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4) 

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4) 

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4) 

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%* (see Item 4) 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     

     

     

    CUSIP No. 98422L107   13G   Page 2 of 9 Pages
         
    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital GP, LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    [   ]

    (b)    [   ]

     
    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%* (see Item 4) 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

     

     

    CUSIP No. 98422L107   13G   Page 3 of 9 Pages
         
    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital IM, L.P.

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    [   ]

    (b)    [   ]

     
    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%* (see Item 4) 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     

     

     

    CUSIP No. 98422L107   13G   Page 4 of 9 Pages
         
    1.

    NAMES OF REPORTING PERSONS

     

    Sessa Capital IM GP, LLC

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    [   ]

    (b)    [   ]

     
    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%* (see Item 4) 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

     

     

     

    CUSIP No. 98422L107   13G   Page 5 of 9 Pages
         
    1.

    NAMES OF REPORTING PERSONS

     

    John Petry

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)    [   ]

    (b)    [   ]

     
    3.

    SEC USE ONLY

     

     
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    6.

    SHARED VOTING POWER

     

     

    7.

    SOLE DISPOSITIVE POWER

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

    8.

    SHARED DISPOSITIVE POWER

     

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    6,607,100 Shares (as defined in Item 2)(including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)* (see Item 4)

     
    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions)    [  ]

     

     
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.99%* (see Item 4) 

     
    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

     

     

     

     

    CUSIP No. 98422L107   13G   Page 6 of 9 Pages

     

    *As more fully described in Item 4, these shares of Common Stock are issuable upon conversion of convertible notes that are subject to a 9.99% beneficial ownership blocker and the percentage set forth on row (11) and the number of shares of Common Stock set forth on rows (5), (7) and (9) give effect to such blocker.

     

    Item 1. (a)

    Name of Issuer

    Xeris Pharmaceuticals, Inc. (or the “Company”)

         
      (b)

    Address of Issuer’s Principal Executive Office

    180 North Lasalle Street, Suite 1800

    Chicago, IL 60601

         
    Item 2. (a)

    Name of Person Filing

    1. Sessa Capital (Master), L.P.

    2. Sessa Capital GP, LLC

    3. Sessa Capital IM, L.P.

    4. Sessa Capital IM GP, LLC

    5. John Petry

     

    This statement is filed by the persons listed in this Item 2(a), who are collectively referred to herein as "Reporting Persons."

         
      (b)

    Address of the Principal Office or, if none, residence

    888 Seventh Avenue, 30th Floor

    New York, New York, 10019

         
      (c)

    Citizenship

    Sessa Capital (Master), L.P. is a Cayman Islands exempted limited partnership. Sessa Capital GP, LLC and Sessa Capital IM GP, LLC are Delaware limited liability companies. Sessa Capital IM, L.P. is a Delaware limited partnership. Mr. Petry is a citizen of the United States.

         
      (d)

    Title of Class of Securities

    Common Stock, par value $0.0001 per share (“Shares”)

         
      (e)

    CUSIP Number

    98422L107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [ ] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) [ ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) [ ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
           
      (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) [ ] Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Not applicable

     

     

     

    CUSIP No. 98422L107   13G   Page 7 of 9 Pages

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount beneficially owned:

    Sessa Capital (Master), L.P. (the “Fund”) directly beneficially owns 6,607,100 Shares (including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)*.

     

    Sessa Capital GP, LLC is the general partner of the Fund and, as a result, may be deemed to beneficially own Shares owned by the Fund.

     

    Sessa Capital IM, L.P. is the investment manager of the Fund and, as a result, may be deemed to beneficially own Shares owned by the Fund.

     

    Sessa Capital IM GP, LLC is the general partner of Sessa Capital IM, L.P. and, as a result, may be deemed to beneficially own Shares beneficially owned by Sessa Capital IM, L.P.

     

    Mr. Petry is the manager of Sessa Capital GP, LLC and Sessa Capital IM GP, LLC and, as a result, may be deemed to beneficially own Shares owned by the Fund.

     

    The number of Shares set forth above and on rows (5), (7) and (9) of the cover page for each Reporting Person are based on the Company's total number of outstanding Shares and assume the conversion of convertible notes directly beneficially owned by the Fund (the "Securities"), subject to the 9.99% Blocker (as defined below).

     

    Pursuant to the terms of the convertible notes directly beneficially owned by the Fund, the Reporting Persons are not entitled to receive any shares of common stock to the extent Reporting Persons after conversion would beneficially own more than 9.99% of the outstanding Shares (the "9.99% Blocker"). The percentage set forth on Row (11) and the number of Shares set forth on rows (5), (7) and (9) of the cover page for each Reporting Person give effect to the 9.99% Blocker. Consequently, at this time, the Reporting Persons are not able to exercise or convert all of the Securities due to the 9.99% Blocker.

       
    (b)

    Percent of class:

    9.99%* (see Item 4(a)), based on 59,411,633 shares of Common Stock outstanding, which is the sum of (i) 48,976,434 shares of Common Stock outstanding as of September 30, 2020, as set forth in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, which was filed with the Securities and Exchange Commission on November 9, 2020, and (ii) 10,435,199 newly issued shares of Common Stock as set forth in Issuer’s Form 8-K filed with the Securities and Exchange Commission on November 16, 2020.

       
    (c) Number of shares as to which the person has:
      (i)

    Sole power to vote or to direct the vote:

     

    Each of the reporting persons may be deemed to have the sole power to vote or direct the vote of 6,607,100 Shares (including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)*.

         
      (ii)

    Shared power to vote or to direct the vote:

     

    Not applicable.

         
      (iii)

    Sole power to dispose or to direct the disposition of:

     

    Each of the reporting persons may be deemed to have the sole power to dispose or direct the disposition of 6,607,100 Shares (including 2,434,641 shares of Common Stock issuable upon conversion of convertible notes)*.

         
      (iv)

    Shared power to dispose or to direct the disposition of:

     

    Not applicable.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ] .

     

     

     

    CUSIP No. 98422L107   13G   Page 8 of 9 Pages

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable

     

     

     

    CUSIP No. 98422L107   13G   Page 9 of 9 Pages

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      Name of Registrant  
           
      By: /s/ John Petry  
        John Petry, individually, as manager of Sessa Capital GP, LLC, the general partner of Sessa Capital (Master), L.P., and as manager of Sessa Capital IM GP, LLC, the general partner of Sessa Capital IM, L.P.  
           
      Date: February 16, 2021  

     

     

     

    SCHEDULE 13G

     

    CUSIP No. 98422L107

     

    EXHIBIT INDEX TO SCHEDULE 13G

     

    EXHIBIT 1

     

    Joint Filing Agreement, dated as of February 16, 2021, by and between Sessa Capital (Master), L.P., Sessa Capital GP, LLC, Sessa Capital IM, L.P., Sessa Capital IM GP, LLC, and John Petry.

     

     

     

    Get the next $XERS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $XERS

    DatePrice TargetRatingAnalyst
    11/11/2024$3.00Overweight → Neutral
    Piper Sandler
    3/28/2024$5.00Outperform
    Oppenheimer
    8/28/2023$4.50Buy
    Craig Hallum
    10/21/2022$4.00Buy
    Jefferies
    4/28/2022$6.50Buy
    Craig Hallum
    2/16/2022$8.00 → $6.00Outperform
    SVB Leerink
    12/31/2021$6.00 → $8.00Outperform
    SVB Leerink
    12/31/2021$4.25 → $5.40Buy
    HC Wainwright & Co.
    More analyst ratings

    $XERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Mcculloch Kevin bought $109,475 worth of shares (25,000 units at $4.38), increasing direct ownership by 1% to 1,708,585 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      6/16/25 4:26:02 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,147 worth of shares (4,515 units at $2.25) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/13/24 4:15:08 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Schmid John P. bought $10,134 worth of shares (4,285 units at $2.37) (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      8/12/24 6:28:50 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Xeris Biopharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Xeris Biopharma from Overweight to Neutral and set a new price target of $3.00

      11/11/24 7:52:12 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Xeris Biopharma with a new price target

      Oppenheimer initiated coverage of Xeris Biopharma with a rating of Outperform and set a new price target of $5.00

      3/28/24 7:52:34 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Xeris Biopharma with a new price target

      Craig Hallum initiated coverage of Xeris Biopharma with a rating of Buy and set a new price target of $4.50

      8/28/23 7:53:14 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    SEC Filings

    See more
    • Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      6/4/25 5:17:41 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      6/3/25 8:04:18 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Xeris Biopharma Holdings Inc.

      EFFECT - Xeris Biopharma Holdings, Inc. (0001867096) (Filer)

      5/14/25 12:15:23 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Mcculloch Kevin bought $109,475 worth of shares (25,000 units at $4.38), increasing direct ownership by 1% to 1,708,585 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      6/16/25 4:26:02 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bormann-Kennedy Barbara-Jean Anne was granted 50,000 shares, increasing direct ownership by 47% to 157,500 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      6/4/25 7:07:24 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Persky Marla was granted 50,000 shares, increasing direct ownership by 47% to 157,500 units (SEC Form 4)

      4 - Xeris Biopharma Holdings, Inc. (0001867096) (Issuer)

      6/4/25 7:05:14 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer

      Kenneth Johnson, PharmD, SVP Global Development & Medical Affairs to retire Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that Dr. Anh Nguyen has joined Xeris as Chief Medical Officer (CMO) succeeding Ken Johnson PharmD, SVP, Global Development and Medical Affairs who will retire April 1, 2025. Dr. Nguyen will develop and lead the entire product portfolio vision and strategic direction for the Medical, Regulatory, Preclinical and Clinical Development, and Pharmacovigilance functions, reporting to John Shannon, X

      2/24/25 8:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Announces CEO Succession Plan

      John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track record of its leadership team Q2 '24 total revenue is anticipated to exceed $47 million, representing more than 23% growth over last year Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced a CEO succession plan effective August 1, 20

      7/8/24 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day

      Company to discuss long-range financial outlook and strategic roadmap for rapid and sustainable growth Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host its first-ever Analyst and Investor Day today to showcase its strategy for sustainable growth and value creation. "We have built a strong foundation through innovation and a relentless commitment to improving patient lives. We will showcase how these achievements have positioned us to take the next bold step in our journey of growth and transformation. We are excited to sh

      6/3/25 7:30:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Announces Details for Analyst & Investor Day

      Hybrid Event Offering In-Person or Virtual Attendance on Tuesday, June 3, 2025 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for its first in-person and virtual analyst and investor day in New York City on Tuesday, June 3, 2025, at 10:00 a.m. EST. The event will feature key opinion leaders (KOLs) Antonio C. Bianco, MD, PhD (University of Texas Medical Branch), Francesco S. Celi, MD, MHSc (UConn Health), and Eliza B. Geer, MD (Memorial Sloan Kettering Cancer Center), who will join company management to di

      5/20/25 7:30:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Financials

    Live finance-specific insights

    See more
    • Xeris Biopharma Reports Record First Quarter 2025 Financial Results

      Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3rd in New York City Hosts conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the first quarter ended March 31, 2025, and updated its fiscal 2025 total revenue guidance. "We're very pleased with our strong start to the year,

      5/8/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

      Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its first quarter 2025 financial results before the open of the U.S. financial markets on Thursday, May 8, 2025. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company's financial and operational results. To pre-register for the call, please go to the following link: https://www.netroadshow.com/events/login?show=7ba30d1f&confId=80481 After registering, a confirmation email will be sen

      5/1/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance

      Achieved record quarterly and full-year total revenue of $60M and $203M, growing 35% and 24% versus prior year Recorlev® revenue more than doubled versus prior year and grew 28% in the fourth quarter sequentially Ended Q4 with over $71M in cash, generating $2M in cash in the fourth quarter Provides full-year 2025 total revenue guidance of $255M-$275M, representing a growth of over 30% at the mid-point of the range Hosting conference call and webcast today at 8:30 a.m. ET Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today annou

      3/6/25 7:00:00 AM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 5:17:37 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Xeris Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      2/13/24 4:34:36 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Xeris Biopharma Holdings Inc.

      SC 13G - Xeris Biopharma Holdings, Inc. (0001867096) (Subject)

      1/26/24 4:23:46 PM ET
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care